{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T22:15:22Z","timestamp":1777414522131,"version":"3.51.4"},"reference-count":50,"publisher":"Japanese Society of Internal Medicine","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2026,2,1]]},"DOI":"10.2169\/internalmedicine.5880-25","type":"journal-article","created":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T22:07:31Z","timestamp":1752703651000},"page":"497-502","source":"Crossref","is-referenced-by-count":3,"title":["Urinary Retention Triggered by Urethritis in Olanzapine-induced Diabetic Ketoacidosis"],"prefix":"10.2169","volume":"65","author":[{"given":"Hideyuki","family":"Murakami","sequence":"first","affiliation":[{"name":"Internal Medicine, Ashoro National Health Insurance Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuaki","family":"Norita","sequence":"additional","affiliation":[{"name":"Internal Medicine, Ashoro National Health Insurance Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiro","family":"Ikeda","sequence":"additional","affiliation":[{"name":"Internal Medicine, Ashoro National Health Insurance Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Stephenson CM, Pilowsky LS. Psychopharmacology of olanzapine. A review. Br J Psychiatry Suppl 38: 52-58, 1999.","DOI":"10.1192\/S0007125000298115"},{"key":"2","doi-asserted-by":"publisher","unstructured":"2. Goldstein LE, Sporn J, Brown S, et al. New-onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment. Psychosomatics 40: 438-443, 1999.","DOI":"10.1016\/S0033-3182(99)71210-7"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Bonanno DG, Davydov L, Botts SR. Olanzapine-induced diabetes mellitus. Ann Pharmacother 35: 563-565, 2001.","DOI":"10.1345\/1542-6270(2001)035<0563:OIDM>2.0.CO;2"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Ragucci KR, Wells BJ. Olanzapine-induced diabetic ketoacidosis. Ann Pharmacother 35: 1556-1558, 2001.","DOI":"10.1345\/aph.1A157"},{"key":"5","doi-asserted-by":"publisher","unstructured":"5. Koller EA, Doraiswamy PM. Olanzapine-associated diabetes mellitus. Pharmacotherapy 22: 841-852, 2002.","DOI":"10.1592\/phco.22.11.841.33629"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Varma MK, Connolly K, Fulton B. Life-threatening hyperglycemia and acidosis related to olanzapine: a case report and review of the literature. J Intensive Care Med 22: 52-55, 2007.","DOI":"10.1177\/0885066606295823"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Vuk A, Kuzman MR, Baretic M, Osvatic MM. Diabetic ketoacidosis associated with antipsychotic drugs: case reports and a review of literature. Psychiatr Danub 29: 121-135, 2017.","DOI":"10.24869\/psyd.2017.121"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Sa YK, Yang H, Jung HK, et al. Olanzapine-induced diabetic ketoacidosis and neuroleptic malignant syndrome with rhabdomyolysis: a case report. Endocrinol Metab (Seoul) 28: 70-75, 2013.","DOI":"10.3803\/EnM.2013.28.1.70"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Jain AK, Shah A, Bhat G. Olanzapine-induced diabetic ketoacidosis: a reversible etiology overlooked in psychiatric patients. AACE Clin Case Rep 10: 14-16, 2023.","DOI":"10.1016\/j.aace.2023.10.006"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Polcwiartek C, Vang T, Bruhn CH, Hashemi N, Rosenzweig M, Nielsen J. Diabetic ketoacidosis in patients exposed to antipsychotics: a systematic literature review and analysis of Danish adverse drug event reports. Psychopharmacology (Berl) 233: 3663-3672, 2016.","DOI":"10.1007\/s00213-016-4411-x"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Carli M, Kolachalam S, Longoni B, et al. Atypical antipsychotics and metabolic syndrome: from molecular mechanisms to clinical differences. Pharmaceuticals (Basel) 14: 238, 2021.","DOI":"10.3390\/ph14030238"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Sep\u00falveda-Lizcano L, Arenas-Villamizar VV, Jaimes-Duarte EB, et al. Metabolic adverse effects of psychotropic drug therapy: a systematic review. Eur J Investig Health Psychol Educ 13: 1505-1520, 2023.","DOI":"10.3390\/ejihpe13080110"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Jin H, Meyer JM, Jeste DV. Phenomenology of and risk factors for new-onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics: an analysis of 45 published cases. Ann Clin Psychiatry 14: 59-64, 2002.","DOI":"10.3109\/10401230209147399"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Rojo LE, Gaspar PA, Silva H, et al. Metabolic syndrome and obesity among users of second generation antipsychotics: a global challenge for modern psychopharmacology. Pharmacol Res 101: 74-85, 2015.","DOI":"10.1016\/j.phrs.2015.07.022"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Barton BB, Segger F, Fischer K, Obermeier M, Musil R. Update on weight-gain caused by antipsychotics: a systematic review and meta-analysis. Expert Opin Drug Saf 19: 295-314, 2020.","DOI":"10.1080\/14740338.2020.1713091"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Bernardo M, Rico-Villademoros F, Garc\u00eda-Rizo C, Rojo R, G\u00f3mez-Huelgas R. Real-world data on the adverse metabolic effects of second-generation antipsychotics and their potential determinants in adult patients: a systematic review of population-based studies. Adv Ther 38: 2491-2512, 2021.","DOI":"10.1007\/s12325-021-01689-8"},{"key":"17","doi-asserted-by":"publisher","unstructured":"17. Seaburg HL, McLendon BM, Doraiswamy PM. Olanzapine-associated severe hyperglycemia, ketonuria, and acidosis: case report and review of literature. Pharmacotherapy 21: 1448-1454, 2001.","DOI":"10.1592\/phco.21.17.1448.34421"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Nakamura M, Nagamine T. Severe hyperglycemia induced by olanzapine was improved with a recovery of insulin secretion after switching to risperidone and introducing insulin therapy. Intern Med 49: 2635-2637, 2010.","DOI":"10.2169\/internalmedicine.49.4397"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Nakamura M, Masaoka Y, Nagamine T. Olanzapine-induced severe hyperglycemia was completely reversed by the restoration of insulin secretion after switching to aripiprazole and initiating insulin therapy. Clin Neuropsychopharmacol Ther 5: 29-33, 2014.","DOI":"10.5234\/cnpt.5.29"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Kinoshita H, Miyagatani Y, Murao M, Kamimura Y. Regular follow-up of olanzapine blood levels and impaired glucose tolerance in olanzapine-induced diabetic ketoacidosis: a case report. Clin Neuropsychopharmacol Ther 5: 1-4, 2014.","DOI":"10.5234\/cnpt.5.1"},{"key":"21","unstructured":"21. Muench J, Hamer AM. Adverse effects of antipsychotic medications. Am Fam Physician 81: 617-622, 2010."},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Bhana N, Foster RH, Olney R, Plosker GL. Olanzapine: an updated review of its use in the management of schizophrenia. Drugs 61: 111-161, 2001.","DOI":"10.2165\/00003495-200161010-00011"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Worrel JA, Marken PA, Beckman SE, Ruehter VL. Atypical antipsychotic agents: a critical review. Am J Health Syst Pharm 57: 238-255, 2000.","DOI":"10.1093\/ajhp\/57.3.238"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Lieberman JA, Stroup TS, McEvoy JP, et al.; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353: 1209-1223, 2005.","DOI":"10.1056\/NEJMoa051688"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Koro CE, Fedder DO, L&apos;Italien GJ, et al. Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study. BMJ 325: 243, 2002.","DOI":"10.1136\/bmj.325.7358.243"},{"key":"26","doi-asserted-by":"publisher","unstructured":"26. Tecott LH, Sun LM, Akana SF, et al. Eating disorder and epilepsy in mice lacking 5-HT<sup>2c<\/sup> serotonin receptors. Nature 374: 542-546, 1995.","DOI":"10.1038\/374542a0"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Orthen-Gambill N, Salomon M. Differential effects of psychotropic drugs on feeding in rats: is histamine blockade involved? Pharmacol Biochem Behav 36: 837-841, 1990.","DOI":"10.1016\/0091-3057(90)90086-W"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Murashita M, Kusumi I, Inoue T, et al. Olanzapine increases plasma ghrelin level in patients with schizophrenia. Psychoneuroendocrinology 30: 106-110, 2005.","DOI":"10.1016\/j.psyneuen.2004.05.008"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Ikegami M, Ikeda H, Ohashi T, et al. Olanzapine increases hepatic glucose production through the activation of hypothalamic adenosine 5&apos;-monophosphate-activated protein kinase. Diabetes Obes Metab 15: 1128-1135, 2013.","DOI":"10.1111\/dom.12148"},{"key":"30","doi-asserted-by":"publisher","unstructured":"30. Ikegami M, Ikeda H, Ohashi T, et al. Olanzapine-induced hyperglycemia: possible involvement of histaminergic, dopaminergic and adrenergic functions in the central nervous system. Neuroendocrinology 98: 224-232, 2013.","DOI":"10.1159\/000356119"},{"key":"31","doi-asserted-by":"publisher","unstructured":"31. Babkin P, George Thompson AM, Iancu CV, Walters DE, Choe JY. Antipsychotics inhibit glucose transport: determination of olanzapine binding site in <i>Staphylococcus epidermidis<\/i> glucose\/H<sup>+<\/sup> symporter. FEBS Open Bio 5: 335-340, 2015.","DOI":"10.1016\/j.fob.2015.04.006"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Vedal TSJ, Steen NE, Birkeland KI, et al. Adipokine levels are associated with insulin resistance in antipsychotics users independently of BMI. Psychoneuroendocrinology 103: 87-95, 2019.","DOI":"10.1016\/j.psyneuen.2019.01.001"},{"key":"33","doi-asserted-by":"publisher","unstructured":"33. Weston-Green K, Huang XF, Deng C. Second generation antipsychotic-induced type 2 diabetes: a role for the muscarinic M3 receptor. CNS Drugs 27: 1069-1080, 2013.","DOI":"10.1007\/s40263-013-0115-5"},{"key":"34","doi-asserted-by":"publisher","unstructured":"34. Grajales D, Ferreira V, Valverde \u00c1M. Second-generation antipsychotics and dysregulation of glucose metabolism: beyond weight gain. Cells 8: 1336, 2019.","DOI":"10.3390\/cells8111336"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Ninagawa S, Tada S, Okumura M, et al. Antipsychotic olanzapine-induced misfolding of proinsulin in the endoplasmic reticulum accounts for atypical development of diabetes. Elife 9: e60970, 2020.","DOI":"10.7554\/eLife.60970"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Benoit SR, Zhang Y, Geiss LS, Gregg EW, Albright A. Trends in diabetic ketoacidosis hospitalizations and in-hospital mortality - United States, 2000-2014. MMWR Morb Mortal Wkly Rep 67: 362-365, 2018.","DOI":"10.15585\/mmwr.mm6712a3"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Danne T, Garg S, Peters AL, et al. International consensus on risk management of diabetic ketoacidosis in patients with type 1 diabetes treated with sodium-glucose cotransporter (SGLT) inhibitors. Diabetes Care 42: 1147-1154, 2019.","DOI":"10.2337\/dc18-2316"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Umapathysivam MM, Morgan B, Inglis JM, et al. SGLT2 inhibitor-associated ketoacidosis vs type 1 diabetes-associated ketoacidosis. JAMA Netw Open 7: e242744, 2024.","DOI":"10.1001\/jamanetworkopen.2024.2744"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Musso G, Saba F, Cassader M, Gambino R. Diabetic ketoacidosis with SGLT2 inhibitors. BMJ 371: m4147, 2020.","DOI":"10.1136\/bmj.m4147"},{"key":"40","doi-asserted-by":"publisher","unstructured":"40. Takahashi M, Ohishi S, Katsumi C, Moriya T, Miyaoka H. Rapid onset of quetiapine-induced diabetic ketoacidosis in an elderly patient: a case report. Pharmacopsychiatry 38: 183-184, 2005.","DOI":"10.1055\/s-2005-871245"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Henderson DC, Cagliero E, Copeland PM, et al. Elevated hemoglobin A1c as a possible indicator of diabetes mellitus and diabetic ketoacidosis in schizophrenia patients receiving atypical antipsychotics. J Clin Psychiatry 68: 533-541, 2007.","DOI":"10.4088\/JCP.v68n0407"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. Daneshgari F, Liu G, Birder L, Hanna-Mitchell AT, Chacko S. Diabetic bladder dysfunction: current translational knowledge. J Urol 182: S18-S26, 2009.","DOI":"10.1016\/j.juro.2009.08.070"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. Kirschner-Hermanns R, Daneshgari F, Vahabi B, Birder L, Oelke M, Chacko S. Does diabetes mellitus-induced bladder remodeling affect lower urinary tract function? ICI-RS 2011. Neurourol Urodyn 31: 359-364, 2012.","DOI":"10.1002\/nau.22228"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44. Yuan Z, Tang Z, He C, Tang W. Diabetic cystopathy: a review. J Diabetes 7: 442-447, 2015.","DOI":"10.1111\/1753-0407.12272"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45. Liu G, Daneshgari F. Diabetic bladder dysfunction. Chin Med J (Engl) 127: 1357-1364, 2014.","DOI":"10.3760\/cma.j.issn.0366-6999.20132407"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46. Martonosi \u00c1R, P\u00e1zm\u00e1ny P, Kiss S, Dembrovszky F, O\u0161tarija\u0161 E, Szab\u00f3 L. Urodynamics in early diagnosis of diabetic bladder dysfunction in women: a systematic review and meta-analysis. Med Sci Monit 28: e937166, 2022.","DOI":"10.12659\/MSM.937166"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47. Arrellano-Valdez F, Urrutia-Osorio M, Arroyo C, Soto-Vega E. A comprehensive review of urologic complications in patients with diabetes. Springerplus 3: 549, 2014.","DOI":"10.1186\/2193-1801-3-549"},{"key":"48","unstructured":"48. Serlin DC, Heidelbaugh JJ, Stoffel JT. Urinary retention in adults: evaluation and initial management. Am Fam Physician 98: 496-503, 2018."},{"key":"49","doi-asserted-by":"crossref","unstructured":"49. Lee CY, Kim CS, Cho WJ. Characteristics of urinary retention in female inpatients managed with medical treatments. Korean J Urol 56: 817-822, 2015.","DOI":"10.4111\/kju.2015.56.12.817"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50. Wilson DR, D&apos;Souza L, Sarkar N, Newton M, Hammond C. New-onset diabetes and ketoacidosis with atypical antipsychotics. Schizophr Res 59: 1-6, 2003.","DOI":"10.1016\/S0920-9964(01)00331-0"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/3\/65_5880-25\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T03:47:09Z","timestamp":1770436029000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/3\/65_5880-25\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,1]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.5880-25","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,1]]},"article-number":"5880-25"}}